Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
by
Hoffmann, Maike
, Triola, Gemma
, Ismail, Shehab
, Zimmermann, Gunther
, Bastiaens, Philippe I H
, Waldmann, Herbert
, Hahn, Stephan A
, Vartak, Nachiket
, Papke, Björn
, Chandra, Anchal
, Wittinghofer, Alfred
in
Adenocarcinoma - drug therapy
/ Adenocarcinoma - genetics
/ Adenocarcinoma - metabolism
/ Animals
/ Benzimidazoles - chemistry
/ Benzimidazoles - metabolism
/ Benzimidazoles - pharmacology
/ Benzimidazoles - therapeutic use
/ Binding Sites
/ Carcinoma, Pancreatic Ductal - drug therapy
/ Carcinoma, Pancreatic Ductal - genetics
/ Carcinoma, Pancreatic Ductal - metabolism
/ Cell Line
/ Cell Line, Tumor
/ Cell Proliferation - drug effects
/ Cell research
/ Crystals
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - antagonists & inhibitors
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - chemistry
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - metabolism
/ Dogs
/ Fluorescence microscopy
/ Humans
/ Hydrogen Bonding
/ MAP Kinase Signaling System - drug effects
/ Mice
/ Mice, Nude
/ Mitogen-Activated Protein Kinases - metabolism
/ Models, Molecular
/ Molecular Conformation
/ Neoplasm Transplantation
/ Oncogene Protein p21(ras) - antagonists & inhibitors
/ Oncogene Protein p21(ras) - genetics
/ Oncogene Protein p21(ras) - metabolism
/ Peptides
/ Properties
/ Protein Binding - drug effects
/ Ras genes
/ Signal Transduction - drug effects
/ Structure
2013
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
by
Hoffmann, Maike
, Triola, Gemma
, Ismail, Shehab
, Zimmermann, Gunther
, Bastiaens, Philippe I H
, Waldmann, Herbert
, Hahn, Stephan A
, Vartak, Nachiket
, Papke, Björn
, Chandra, Anchal
, Wittinghofer, Alfred
in
Adenocarcinoma - drug therapy
/ Adenocarcinoma - genetics
/ Adenocarcinoma - metabolism
/ Animals
/ Benzimidazoles - chemistry
/ Benzimidazoles - metabolism
/ Benzimidazoles - pharmacology
/ Benzimidazoles - therapeutic use
/ Binding Sites
/ Carcinoma, Pancreatic Ductal - drug therapy
/ Carcinoma, Pancreatic Ductal - genetics
/ Carcinoma, Pancreatic Ductal - metabolism
/ Cell Line
/ Cell Line, Tumor
/ Cell Proliferation - drug effects
/ Cell research
/ Crystals
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - antagonists & inhibitors
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - chemistry
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - metabolism
/ Dogs
/ Fluorescence microscopy
/ Humans
/ Hydrogen Bonding
/ MAP Kinase Signaling System - drug effects
/ Mice
/ Mice, Nude
/ Mitogen-Activated Protein Kinases - metabolism
/ Models, Molecular
/ Molecular Conformation
/ Neoplasm Transplantation
/ Oncogene Protein p21(ras) - antagonists & inhibitors
/ Oncogene Protein p21(ras) - genetics
/ Oncogene Protein p21(ras) - metabolism
/ Peptides
/ Properties
/ Protein Binding - drug effects
/ Ras genes
/ Signal Transduction - drug effects
/ Structure
2013
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
by
Hoffmann, Maike
, Triola, Gemma
, Ismail, Shehab
, Zimmermann, Gunther
, Bastiaens, Philippe I H
, Waldmann, Herbert
, Hahn, Stephan A
, Vartak, Nachiket
, Papke, Björn
, Chandra, Anchal
, Wittinghofer, Alfred
in
Adenocarcinoma - drug therapy
/ Adenocarcinoma - genetics
/ Adenocarcinoma - metabolism
/ Animals
/ Benzimidazoles - chemistry
/ Benzimidazoles - metabolism
/ Benzimidazoles - pharmacology
/ Benzimidazoles - therapeutic use
/ Binding Sites
/ Carcinoma, Pancreatic Ductal - drug therapy
/ Carcinoma, Pancreatic Ductal - genetics
/ Carcinoma, Pancreatic Ductal - metabolism
/ Cell Line
/ Cell Line, Tumor
/ Cell Proliferation - drug effects
/ Cell research
/ Crystals
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - antagonists & inhibitors
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - chemistry
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - metabolism
/ Dogs
/ Fluorescence microscopy
/ Humans
/ Hydrogen Bonding
/ MAP Kinase Signaling System - drug effects
/ Mice
/ Mice, Nude
/ Mitogen-Activated Protein Kinases - metabolism
/ Models, Molecular
/ Molecular Conformation
/ Neoplasm Transplantation
/ Oncogene Protein p21(ras) - antagonists & inhibitors
/ Oncogene Protein p21(ras) - genetics
/ Oncogene Protein p21(ras) - metabolism
/ Peptides
/ Properties
/ Protein Binding - drug effects
/ Ras genes
/ Signal Transduction - drug effects
/ Structure
2013
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Journal Article
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
2013
Request now
and choose the collection method
Overview
The KRAS oncogene product is considered a major target in anticancer drug discovery. However, direct interference with KRAS signalling has not yet led to clinically useful drugs. Correct localization and signalling by farnesylated KRAS is regulated by the prenyl-binding protein PDEδ, which sustains the spatial organization of KRAS by facilitating its diffusion in the cytoplasm. Here we report that interfering with binding of mammalian PDEδ to KRAS by means of small molecules provides a novel opportunity to suppress oncogenic RAS signalling by altering its localization to endomembranes. Biochemical screening and subsequent structure-based hit optimization yielded inhibitors of the KRAS-PDEδ interaction that selectively bind to the prenyl-binding pocket of PDEδ with nanomolar affinity, inhibit oncogenic RAS signalling and suppress in vitro and in vivo proliferation of human pancreatic ductal adenocarcinoma cells that are dependent on oncogenic KRAS. Our findings may inspire novel drug discovery efforts aimed at the development of drugs targeting oncogenic RAS.
Publisher
Nature Publishing Group
Subject
/ Animals
/ Benzimidazoles - pharmacology
/ Benzimidazoles - therapeutic use
/ Carcinoma, Pancreatic Ductal - drug therapy
/ Carcinoma, Pancreatic Ductal - genetics
/ Carcinoma, Pancreatic Ductal - metabolism
/ Cell Proliferation - drug effects
/ Crystals
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - antagonists & inhibitors
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - chemistry
/ Cyclic Nucleotide Phosphodiesterases, Type 6 - metabolism
/ Dogs
/ Humans
/ MAP Kinase Signaling System - drug effects
/ Mice
/ Mitogen-Activated Protein Kinases - metabolism
/ Oncogene Protein p21(ras) - antagonists & inhibitors
/ Oncogene Protein p21(ras) - genetics
/ Oncogene Protein p21(ras) - metabolism
/ Peptides
/ Protein Binding - drug effects
This website uses cookies to ensure you get the best experience on our website.